Canadian Rx-to-OTC Approval Process Could Be Smoother, GSK Exec Says
This article was originally published in The Tan Sheet
Executive Summary
Canada's Rx-to-OTC switch process should be streamlined and made more industry-friendly, according to GlaxoSmithKline regulatory executive Jennifer Denomme
You may also be interested in...
Applying Drug Model To Regulating Canada’s Supplements Sparks Opposition
A proposed amendment to Canada's Food and Drugs Act could move the regulation of natural health products closer to the pharmaceutical regulatory model, according to the Canadian Health Food Association
NDMAC Urges OTC Exclusivity In Canada Similar To U.S. Model
Canadian regulators should allow three-year exclusivity for innovations in both existing and new nonprescription drug products, the country's self-care industry trade group says
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.